{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:22:16Z","timestamp":1791638536951,"version":"4.3.4"},"publisher-location":"Cham","reference-count":135,"publisher":"Springer Nature Switzerland","isbn-type":[{"value":"9783031963636","type":"print"},{"value":"9783031963643","type":"electronic"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1007\/978-3-031-96364-3_11","type":"book-chapter","created":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T08:05:49Z","timestamp":1759737949000},"page":"271-292","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Novel Ways of Targeting the Dopamine Transporter"],"prefix":"10.1007","author":[{"given":"Yibin","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanming","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaili","family":"Aggarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole Valente","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,7]]},"reference":[{"key":"11_CR1","doi-asserted-by":"publisher","first-page":"656475","DOI":"10.3389\/fnins.2021.656475","volume":"15","author":"M Hersey","year":"2021","unstructured":"Hersey M et al (2021) Psychostimulant use disorder, an unmet therapeutic goal: can modafinil narrow the gap? Front Neurosci 15:656475\u2013656475","journal-title":"Front Neurosci"},{"key":"11_CR2","unstructured":"NIDA (2018) Understanding drug use and addiction DrugFacts. Available from: https:\/\/nida.nih.gov\/publications\/drugfacts\/understanding-drug-use-addiction"},{"issue":"2","key":"11_CR3","doi-asserted-by":"publisher","first-page":"339","DOI":"10.5209\/psic.84045","volume":"19","author":"A Sanz Cort\u00e9s","year":"2022","unstructured":"Sanz Cort\u00e9s A (2022) Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, Text Revision (DSM-5-TR). American Psychiatric Association, 2022. https:\/\/doi.org\/10.1176\/appi.books.9780890425787. Psicooncolog\u00eda 19(2):339\u2013340","journal-title":"Psicooncolog\u00eda"},{"key":"11_CR4","volume-title":"Treatment of stimulant use disorders","author":"SAMHSA","year":"2020","unstructured":"SAMHSA (2020) Treatment of stimulant use disorders. Substance Abuse and Mental Health Services Administration, Rockville"},{"key":"11_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.dcn.2020.100789","volume":"43","author":"F Mottarlini","year":"2020","unstructured":"Mottarlini F et al (2020) Repeated cocaine exposure during adolescence impairs recognition memory in early adulthood: a role for BDNF signaling in the perirhinal cortex. Dev Cogn Neurosci 43:100789","journal-title":"Dev Cogn Neurosci"},{"key":"11_CR6","volume-title":"Facing addiction in America: the surgeon general\u2019s report on alcohol, drugs, and health","author":"Substance Abuse and Mental Health Services Administration (US); Office of the Surgeon General (US)","year":"2016","unstructured":"Substance Abuse and Mental Health Services Administration (US); Office of the Surgeon General (US) (2016) Chapter 2 \u2013 The neurobiology of substance use, misuse, and addiction. In: Facing addiction in America: the surgeon general\u2019s report on alcohol, drugs, and health. US Department of Health and Human Services, Washington, DC"},{"key":"11_CR7","unstructured":"Zhao W (2008) Mechanisms mediating sex differences in the effects of cocaine. PhD thesis, University of Michigan"},{"issue":"12","key":"11_CR8","first-page":"509","volume":"52","author":"KT Brady","year":"1991","unstructured":"Brady KT et al (1991) Cocaine-induced psychosis. J Clin Psychiatry 52(12):509\u2013512","journal-title":"J Clin Psychiatry"},{"key":"11_CR9","doi-asserted-by":"publisher","first-page":"S460","DOI":"10.1016\/S0924-9338(09)70693-5","volume":"24","author":"M Stankovic","year":"2009","unstructured":"Stankovic M et al (2009) P01-72 Cocaine dependence produce psychiatric symptoms \u2013 a case report. Eur Psychiatry 24:S460","journal-title":"Eur Psychiatry"},{"key":"11_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.eurpsy.2016.11.006","volume":"42","author":"C Roncero","year":"2017","unstructured":"Roncero C et al (2017) Higher severity of cocaine addiction is associated with tactile and somatic hallucinations. Eur Psychiatry 42:63\u201369","journal-title":"Eur Psychiatry"},{"key":"11_CR11","unstructured":"CDC (2024) Stimulant overdose. [cited 2024 Feb 11]. Available from: https:\/\/www.cdc.gov\/drugoverdose\/deaths\/stimulant-overdose.html"},{"key":"11_CR12","unstructured":"FAS (2022) 10 Most common reasons for addiction relapse: family addiction specialist: addiction counselor. [cited 2022 Jan 21]. Available from: https:\/\/www.familyaddictionspecialist.com\/blog\/10-most-common-reasons-for-addiction-relapse"},{"issue":"5","key":"11_CR13","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00424-003-1100-5","volume":"447","author":"LE Eiden","year":"2004","unstructured":"Eiden LE et al (2004) The vesicular amine transporter family (SLC18): amine\/proton antiporters required for vesicular accumulation and regulated exocytotic secretion of monoamines and acetylcholine. Pflugers Arch 447(5):636\u2013640","journal-title":"Pflugers Arch"},{"issue":"6","key":"11_CR14","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1007\/BF02256330","volume":"10","author":"R Chen","year":"2003","unstructured":"Chen R et al (2003) Demonstration of functional coupling between dopamine synthesis and its packaging into synaptic vesicles. J Biomed Sci 10(6):774\u2013781","journal-title":"J Biomed Sci"},{"issue":"2","key":"11_CR15","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.brainresrev.2007.07.014","volume":"56","author":"A Alcaro","year":"2007","unstructured":"Alcaro A, Huber R, Panksepp J (2007) Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev 56(2):283\u2013321","journal-title":"Brain Res Rev"},{"issue":"1","key":"11_CR16","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1080\/02791072.2012.662112","volume":"44","author":"K Blum","year":"2012","unstructured":"Blum K et al (2012) Sex, drugs, and rock \u201cN\u201d roll: hypothesizing common mesolimbic activation as a function of reward gene polymorphisms. J Psychoactive Drugs 44(1):38\u201355","journal-title":"J Psychoactive Drugs"},{"key":"11_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.neubiorev.2017.04.007","volume":"78","author":"N Boot","year":"2017","unstructured":"Boot N et al (2017) Creative cognition and dopaminergic modulation of fronto-striatal networks: integrative review and research agenda. Neurosci Biobehav Rev 78:13\u201323","journal-title":"Neurosci Biobehav Rev"},{"issue":"3","key":"11_CR18","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ajpath.2015.09.023","volume":"186","author":"SX Luo","year":"2016","unstructured":"Luo SX, Huang EJ (2016) Dopaminergic neurons and brain reward pathways: from neurogenesis to circuit assembly. Am J Pathol 186(3):478\u2013488","journal-title":"Am J Pathol"},{"key":"11_CR19","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1159\/000324065","volume":"30","author":"EL Gardner","year":"2011","unstructured":"Gardner EL (2011) Addiction and brain reward and antireward pathways. Adv Psychosom Med 30:22\u201360","journal-title":"Adv Psychosom Med"},{"key":"11_CR20","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.brainres.2009.12.093","volume":"1321","author":"C Chavez","year":"2010","unstructured":"Chavez C et al (2010) The effect of estrogen on dopamine and serotonin receptor and transporter levels in the brain: an autoradiography study. Brain Res 1321:51\u201359","journal-title":"Brain Res"},{"issue":"4","key":"11_CR21","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1002\/prot.22601","volume":"78","author":"PC Gedeon","year":"2010","unstructured":"Gedeon PC et al (2010) Molecular dynamics of leucine and dopamine transporter proteins in a model cell membrane lipid bilayer. Proteins 78(4):797\u2013811","journal-title":"Proteins"},{"issue":"1","key":"11_CR22","doi-asserted-by":"publisher","first-page":"12.16.1","DOI":"10.1002\/cpph.32","volume":"79","author":"S Aggarwal","year":"2017","unstructured":"Aggarwal S, Mortensen OV (2017) Overview of monoamine transporters. Curr Protoc Pharmacol 79(1):12.16.1\u201312.16.17","journal-title":"Curr Protoc Pharmacol"},{"issue":"8025","key":"11_CR23","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1038\/s41586-024-07796-0","volume":"632","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) Dopamine reuptake and inhibitory mechanisms in human dopamine transporter. Nature (London) 632(8025):686\u2013694","journal-title":"Nature (London)"},{"issue":"6","key":"11_CR24","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1038\/nsmb.3029","volume":"22","author":"A Penmatsa","year":"2015","unstructured":"Penmatsa A, Wang KH, Gouaux E (2015) X-ray structures of Drosophila dopamine transporter in complex with nisoxetine and reboxetine. Nat Struct Mol Biol 22(6):506\u2013508","journal-title":"Nat Struct Mol Biol"},{"issue":"49","key":"11_CR25","doi-asserted-by":"publisher","first-page":"eabl3857","DOI":"10.1126\/sciadv.abl3857","volume":"7","author":"D Yang","year":"2021","unstructured":"Yang D, Gouaux E (2021) Illumination of serotonin transporter mechanism and role of the allosteric site. Sci Adv 7(49):eabl3857","journal-title":"Sci Adv"},{"issue":"1","key":"11_CR26","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1038\/s41467-021-22385-9","volume":"12","author":"S Pidathala","year":"2021","unstructured":"Pidathala S et al (2021) Structural basis of norepinephrine recognition and transport inhibition in neurotransmitter transporters. Nat Commun 12(1):2199\u20132199","journal-title":"Nat Commun"},{"issue":"9","key":"11_CR27","doi-asserted-by":"publisher","first-page":"e56427","DOI":"10.7554\/eLife.56427","volume":"2020","author":"JA Coleman","year":"2020","unstructured":"Coleman JA et al (2020) Chemical and structural investigation of the paroxetine-human serotonin transporter complex. elife 2020(9):e56427\u2013e56438","journal-title":"elife"},{"issue":"2","key":"11_CR28","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s41594-018-0026-8","volume":"25","author":"JA Coleman","year":"2018","unstructured":"Coleman JA, Gouaux E (2018) Structural basis for recognition of diverse antidepressants by the human serotonin transporter. Nat Struct Mol Biol 25(2):170\u2013175","journal-title":"Nat Struct Mol Biol"},{"issue":"7599","key":"11_CR29","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nature17629","volume":"532","author":"JA Coleman","year":"2016","unstructured":"Coleman JA, Green EM, Gouaux E (2016) X-ray structures and mechanism of the human serotonin transporter. Nature (London) 532(7599):334\u2013339","journal-title":"Nature (London)"},{"issue":"7754","key":"11_CR30","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1038\/s41586-019-1135-1","volume":"569","author":"JA Coleman","year":"2019","unstructured":"Coleman JA et al (2019) Serotonin transporter\u2013ibogaine complexes illuminate mechanisms of inhibition and transport. Nature 569(7754):141\u2013145","journal-title":"Nature"},{"issue":"7474","key":"11_CR31","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/nature12533","volume":"503","author":"A Penmatsa","year":"2013","unstructured":"Penmatsa A, Wang KH, Gouaux E (2013) X-ray structure of dopamine transporter elucidates antidepressant mechanism. Nature 503(7474):85\u201390","journal-title":"Nature"},{"issue":"1","key":"11_CR32","doi-asserted-by":"publisher","first-page":"5063","DOI":"10.1038\/s41467-021-25363-3","volume":"12","author":"P Plenge","year":"2021","unstructured":"Plenge P et al (2021) The antidepressant drug vilazodone is an allosteric inhibitor of the serotonin transporter. Nat Commun 12(1):5063\u20135012","journal-title":"Nat Commun"},{"issue":"8025","key":"11_CR33","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1038\/s41586-024-07804-3","volume":"632","author":"JC Nielsen","year":"2024","unstructured":"Nielsen JC et al (2024) Structure of the human dopamine transporter in complex with cocaine. Nature (London) 632(8025):678\u2013685","journal-title":"Nature (London)"},{"issue":"6","key":"11_CR34","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1152\/physiol.00030.2009","volume":"24","author":"LR Forrest","year":"2009","unstructured":"Forrest LR, Rudnick G (2009) The rocking bundle: a mechanism for ion-coupled solute flux by symmetrical transporters. Physiology 24(6):377\u2013386","journal-title":"Physiology"},{"issue":"5052","key":"11_CR35","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1038\/211969a0","volume":"211","author":"O Jardetzky","year":"1966","unstructured":"Jardetzky O (1966) Simple allosteric model for membrane pumps. Nature (London) 211(5052):969\u2013970","journal-title":"Nature (London)"},{"issue":"4","key":"11_CR36","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1085\/jgp.201110652","volume":"138","author":"N Reyes","year":"2011","unstructured":"Reyes N, Tavoulari S (2011) To be, or not to be two sites: that is the question about LeuT substrate binding. J Gen Physiol 138(4):467\u2013471","journal-title":"J Gen Physiol"},{"issue":"6","key":"11_CR37","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1016\/j.molcel.2008.05.008","volume":"30","author":"L Shi","year":"2008","unstructured":"Shi L et al (2008) The mechanism of a neurotransmitter: sodium symporter \u2013 inward release of Na+ and substrate is triggered by substrate in a second binding site. Mol Cell 30(6):667","journal-title":"Mol Cell"},{"issue":"3","key":"11_CR38","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/j.bbagen.2014.04.011","volume":"1850","author":"CJ Loland","year":"2015","unstructured":"Loland CJ (2015) The use of LeuT as a model in elucidating binding sites for substrates and inhibitors in neurotransmitter transporters. Biochim Biophys Acta 1850(3):500\u2013510","journal-title":"Biochim Biophys Acta"},{"issue":"7056","key":"11_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature03978","volume":"437","author":"A Yamashita","year":"2005","unstructured":"Yamashita A et al (2005) Crystal structure of a bacterial homologue of Na+\/Cl\u2212-dependent neurotransmitter transporters. Nature 437(7056):215\u2013223","journal-title":"Nature"},{"issue":"5843","key":"11_CR40","doi-asserted-by":"publisher","first-page":"1390","DOI":"10.1126\/science.1147614","volume":"317","author":"Z Zhou","year":"2007","unstructured":"Zhou Z et al (2007) LeuT-desipramine structure reveals how antidepressants block neurotransmitter reuptake. Science 317(5843):1390\u20131393","journal-title":"Science"},{"key":"11_CR41","doi-asserted-by":"publisher","first-page":"100125","DOI":"10.1016\/j.crphys.2024.100125","volume":"7","author":"H Nguyen","year":"2024","unstructured":"Nguyen H et al (2024) Allosteric modulation of serotonin and dopamine transporters: new insights from computations and experiments. Curr Res Physiol 7:100125","journal-title":"Curr Res Physiol"},{"key":"11_CR42","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.neuropharm.2013.04.026","volume":"72","author":"S Kortagere","year":"2013","unstructured":"Kortagere S et al (2013) Identification of an allosteric modulator of the serotonin transporter with novel mechanism of action. Neuropharmacology 72:282\u2013290","journal-title":"Neuropharmacology"},{"issue":"8","key":"11_CR43","doi-asserted-by":"publisher","first-page":"3718","DOI":"10.1021\/acschemneuro.9b00262","volume":"10","author":"S Aggarwal","year":"2019","unstructured":"Aggarwal S et al (2019) Identification of a novel allosteric modulator of the human dopamine transporter. ACS Chem Neurosci 10(8):3718\u20133730","journal-title":"ACS Chem Neurosci"},{"issue":"7599","key":"11_CR44","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1038\/nature17629","volume":"532","author":"JA Coleman","year":"2016","unstructured":"Coleman JA, Green EM, Gouaux E (2016) X-ray structures and mechanism of the human serotonin transporter. Nature 532(7599):334\u2013339","journal-title":"Nature"},{"issue":"8026","key":"11_CR45","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/s41586-024-07719-z","volume":"632","author":"J Tan","year":"2024","unstructured":"Tan J et al (2024) Molecular basis of human noradrenaline transporter reuptake and inhibition. Nature (London) 632(8026):921\u2013929","journal-title":"Nature (London)"},{"issue":"8025","key":"11_CR46","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1038\/s41586-024-07739-9","volume":"632","author":"DK Srivastava","year":"2024","unstructured":"Srivastava DK et al (2024) Structure of the human dopamine transporter and mechanisms of inhibition. Nature (London) 632(8025):672\u2013677","journal-title":"Nature (London)"},{"key":"11_CR47","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1016\/j.neuropharm.2013.12.023","volume":"79","author":"B O\u2019Neill","year":"2014","unstructured":"O\u2019Neill B et al (2014) Behavior of knock-in mice with a cocaine-insensitive dopamine transporter after virogenetic restoration of cocaine sensitivity in the striatum. Neuropharmacology 79:626\u2013633","journal-title":"Neuropharmacology"},{"issue":"7","key":"11_CR48","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/nn.2146","volume":"11","author":"JA Javitch","year":"2008","unstructured":"Javitch JA et al (2008) The binding sites for cocaine and dopamine in the dopamine transporter overlap. Nat Neurosci 11(7):780\u2013789","journal-title":"Nat Neurosci"},{"key":"11_CR49","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-3-031-21054-9_4","volume":"30","author":"S Aggarwal","year":"2023","unstructured":"Aggarwal S et al (2023) Discovery and development of monoamine transporter ligands. Adv Neurobiol 30:101\u2013129","journal-title":"Adv Neurobiol"},{"key":"11_CR50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugalcdep.2014.12.005","volume":"147","author":"MEA Reith","year":"2015","unstructured":"Reith MEA et al (2015) Behavioral, biological, and chemical perspectives on atypical agents targeting the dopamine transporter. Drug Alcohol Depend 147:1\u201319","journal-title":"Drug Alcohol Depend"},{"issue":"3","key":"11_CR51","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1124\/mol.107.039800","volume":"73","author":"CJ Loland","year":"2008","unstructured":"Loland CJ et al (2008) Relationship between conformational changes in the dopamine transporter and cocaine-like subjective effects of uptake inhibitors. Mol Pharmacol 73(3):813\u2013823","journal-title":"Mol Pharmacol"},{"key":"11_CR52","volume-title":"StatPearls","author":"A Ahuja","year":"2024","unstructured":"Ahuja A, Patel P, Abdijadid S (2024) Benztropine. In: StatPearls. StatPearls Publishing, Treasure Island. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560633\/"},{"issue":"1","key":"11_CR53","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/0304-3940(91)90120-I","volume":"125","author":"K Itoh","year":"1991","unstructured":"Itoh K et al (1991) Intrastriatal dialysis evidence for a direct inhibitory effect of benztropine on dopamine re-uptake. Neurosci Lett 125(1):22\u201324","journal-title":"Neurosci Lett"},{"key":"11_CR54","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/S1054-3589(08)57007-4","volume":"57","author":"G Tanda","year":"2009","unstructured":"Tanda G, Newman AH, Katz JL (2009) Discovery of drugs to treat cocaine dependence: behavioral and neurochemical effects of atypical dopamine transport inhibitors. Adv Pharmacol 57:253\u2013289","journal-title":"Adv Pharmacol"},{"key":"11_CR55","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.neuint.2018.08.008","volume":"123","author":"MJ Tomlinson","year":"2019","unstructured":"Tomlinson MJ et al (2019) Identification of the benztropine analog [125I]GA II 34 binding site on the human dopamine transporter. Neurochem Int 123:34\u201345","journal-title":"Neurochem Int"},{"issue":"3","key":"11_CR56","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1124\/jpet.110.171629","volume":"335","author":"TA Kopajtic","year":"2010","unstructured":"Kopajtic TA et al (2010) Dopamine transporter-dependent and -independent striatal binding of the benztropine analog JHW 007, a cocaine antagonist with low abuse liability. J Pharmacol Exp Ther 335(3):703\u2013714","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"11_CR57","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.neuropharm.2010.08.021","volume":"60","author":"H Bisgaard","year":"2011","unstructured":"Bisgaard H et al (2011) The binding sites for benztropines and dopamine in the dopamine transporter overlap. Neuropharmacology 60(1):182\u2013190","journal-title":"Neuropharmacology"},{"issue":"1","key":"11_CR58","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s00213-017-4739-x","volume":"235","author":"C Zanettini","year":"2018","unstructured":"Zanettini C, Wilkinson DS, Katz JL (2018) Behavioral economic analysis of the effects of N-substituted benztropine analogs on cocaine self-administration in rats. Psychopharmacology 235(1):47\u201358","journal-title":"Psychopharmacology"},{"key":"11_CR59","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.pnpbp.2013.01.016","volume":"44","author":"C Vel\u00e1zquez-S\u00e1nchez","year":"2013","unstructured":"Vel\u00e1zquez-S\u00e1nchez C et al (2013) The atypical dopamine transport inhibitor, JHW 007, prevents amphetamine-induced sensitization and synaptic reorganization within the nucleus accumbens. Prog Neuropsychopharmacol Biol Psychiatry 44:73\u201380","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"7","key":"11_CR60","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.euroneuro.2010.03.005","volume":"20","author":"C Vel\u00e1zquez-S\u00e1nchez","year":"2010","unstructured":"Vel\u00e1zquez-S\u00e1nchez C et al (2010) The high affinity dopamine uptake inhibitor, JHW 007, blocks cocaine-induced reward, locomotor stimulation and sensitization. Eur Neuropsychopharmacol 20(7):501\u2013508","journal-title":"Eur Neuropsychopharmacol"},{"issue":"1","key":"11_CR61","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1124\/jpet.113.208264","volume":"348","author":"T Hiranita","year":"2014","unstructured":"Hiranita T et al (2014) Preclinical efficacy of N-substituted benztropine analogs as antagonists of methamphetamine self-administration in rats. J Pharmacol Exp Ther 348(1):174\u2013191","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"11_CR62","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.theochem.2004.09.028","volume":"712","author":"L Fengyi","year":"2004","unstructured":"Fengyi L et al (2004) Conformational and electrostatic potential study of the benztropine analogs at the dopamine transporter. J Mol Struct 712(1):207\u2013214","journal-title":"J Mol Struct"},{"issue":"1","key":"11_CR63","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1124\/jpet.117.241109","volume":"362","author":"T Hiranita","year":"2017","unstructured":"Hiranita T et al (2017) \u03c3 Receptor effects of N-substituted benztropine analogs: implications for antagonism of cocaine self-administration. J Pharmacol Exp Ther 362(1):2\u201313","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"11_CR64","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/0197-0186(89)90140-X","volume":"15","author":"NA Sharif","year":"1989","unstructured":"Sharif NA et al (1989) Comparative properties of the dopamine transport complex in dog and rodent brain: striatal [(3)H]GBR12935 binding and [(3)H]dopamine uptake. Neurochem Int 15(3):325\u2013332","journal-title":"Neurochem Int"},{"issue":"2","key":"11_CR65","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0014-5793(89)81566-2","volume":"257","author":"RB Rothman","year":"1989","unstructured":"Rothman RB et al (1989) Tight binding dopamine reuptake inhibitors as cocaine antagonists: a strategy for drug development. FEBS Lett 257(2):341\u2013344","journal-title":"FEBS Lett"},{"issue":"1","key":"11_CR66","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.bcp.2007.08.007","volume":"75","author":"RB Rothman","year":"2008","unstructured":"Rothman RB et al (2008) Dopamine transport inhibitors based on GBR12909 and benztropine as potential medications to treat cocaine addiction. Biochem Pharmacol 75(1):2\u201316","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"11_CR67","doi-asserted-by":"publisher","first-page":"3843","DOI":"10.1038\/s41598-019-39872-1","volume":"9","author":"W-L Sun","year":"2019","unstructured":"Sun W-L et al (2019) Mutational effects of human dopamine transporter at tyrosine88, lysine92, and histidine547 on basal and HIV-1 Tat-inhibited dopamine transport. Sci Rep 9(1):3843\u20133843","journal-title":"Sci Rep"},{"issue":"4","key":"11_CR68","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/0091-3057(94)00438-O","volume":"51","author":"SR Tella","year":"1995","unstructured":"Tella SR (1995) Effects of monoamine reuptake inhibitors on cocaine self-administration in rats. Pharmacol Biochem Behav 51(4):687\u2013692","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"11_CR69","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/0014-2999(87)90603-0","volume":"135","author":"BHC Westerink","year":"1987","unstructured":"Westerink BHC et al (1987) Dopamine re-uptake inhibitors show inconsistent effects on the in vivo release of dopamine as measured by intracerebral dialysis in the rat. Eur J Pharmacol 135(2):123\u2013128","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"11_CR70","first-page":"241","volume":"1","author":"A Preti","year":"2000","unstructured":"Preti A (2000) Vanoxerine National Institute on Drug Abuse. Curr Opin Investig Drugs 1(2):241","journal-title":"Curr Opin Investig Drugs"},{"key":"11_CR71","unstructured":"Modafinil Monograph for Professionals (2024) [cited 2024 Feb 14]. Available from: https:\/\/www.drugs.com\/monograph\/modafinil.html#:~:text=Produces%20psychoactive%20and%20euphoric%20effects,schedule%20II%20CNS%20stimulants%20(e.g.%2C"},{"issue":"3","key":"11_CR72","first-page":"327","volume":"79","author":"DE Blocker","year":"2008","unstructured":"Blocker DE et al (2008) In-flight fatigue management and modafinil trial in usaf tanker aircrew. Aviat Space Environ Med 79(3):327\u2013327","journal-title":"Aviat Space Environ Med"},{"issue":"8","key":"11_CR73","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.biopsych.2009.12.015","volume":"67","author":"JW Young","year":"2010","unstructured":"Young JW, Geyer MA (2010) Action of modafinil\u2014increased motivation via the dopamine transporter inhibition and D1 receptors? Biol Psychiatry 67(8):784\u2013787","journal-title":"Biol Psychiatry"},{"key":"11_CR74","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.chemosphere.2019.06.016","volume":"233","author":"W Wilms","year":"2019","unstructured":"Wilms W et al (2019) Nootropic drugs: methylphenidate, modafinil and piracetam \u2013 population use trends, occurrence in the environment, ecotoxicity and removal methods \u2013 a review. Chemosphere 233:771\u2013785","journal-title":"Chemosphere"},{"issue":"3","key":"11_CR75","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jsat.2011.12.014","volume":"43","author":"CAMD Dackis","year":"2012","unstructured":"Dackis CAMD et al (2012) A double-blind, placebo-controlled trial of modafinil for cocaine dependence. J Subst Abus Treat 43(3):303\u2013312","journal-title":"J Subst Abus Treat"},{"key":"11_CR76","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.drugalcdep.2015.12.004","volume":"160","author":"PT Morgan","year":"2016","unstructured":"Morgan PT et al (2016) Modafinil and sleep architecture in an inpatient\u2013outpatient treatment study of cocaine dependence. Drug Alcohol Depend 160:49\u201356","journal-title":"Drug Alcohol Depend"},{"key":"11_CR77","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.neuropharm.2012.06.064","volume":"64","author":"AD Kalechstein","year":"2013","unstructured":"Kalechstein AD et al (2013) Modafinil, but not escitalopram, improves working memory and sustained attention in long-term, high-dose cocaine users. Neuropharmacology 64:472\u2013478","journal-title":"Neuropharmacology"},{"issue":"1","key":"11_CR78","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.drugalcdep.2009.04.015","volume":"104","author":"AL Anderson","year":"2009","unstructured":"Anderson AL et al (2009) Modafinil for the treatment of cocaine dependence. Drug Alcohol Depend 104(1):133\u2013139","journal-title":"Drug Alcohol Depend"},{"key":"11_CR79","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.drugalcdep.2014.05.008","volume":"141","author":"CD Verrico","year":"2014","unstructured":"Verrico CD et al (2014) Treatment with modafinil and escitalopram, alone and in combination, on cocaine-induced effects: a randomized, double blind, placebo-controlled human laboratory study. Drug Alcohol Depend 141:72\u201378","journal-title":"Drug Alcohol Depend"},{"key":"11_CR80","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.pbb.2016.08.009","volume":"150\u2013151","author":"RW Foltin","year":"2016","unstructured":"Foltin RW et al (2016) Modafinil decreases cocaine choice in human cocaine smokers only when the response requirement and the alternative reinforcer magnitude are large. Pharmacol Biochem Behav 150\u2013151:8\u201313","journal-title":"Pharmacol Biochem Behav"},{"issue":"4","key":"11_CR81","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1111\/j.1369-1600.2011.00341.x","volume":"16","author":"R Wuo-Silva","year":"2011","unstructured":"Wuo-Silva R et al (2011) Addictive potential of modafinil and cross-sensitization with cocaine: a pre-clinical study. Addict Biol 16(4):565\u2013579","journal-title":"Addict Biol"},{"issue":"1","key":"11_CR82","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bbr.2009.05.028","volume":"204","author":"RE Bernardi","year":"2009","unstructured":"Bernardi RE et al (2009) Modafinil reinstates a cocaine conditioned place preference following extinction in rats. Behav Brain Res 204(1):250\u2013253","journal-title":"Behav Brain Res"},{"issue":"2","key":"11_CR83","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.drugalcdep.2009.09.002","volume":"106","author":"SK Vosburg","year":"2010","unstructured":"Vosburg SK et al (2010) Modafinil does not serve as a reinforcer in cocaine abusers. Drug Alcohol Depend 106(2):233\u2013236","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"11_CR84","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1016\/j.biopsych.2012.03.022","volume":"72","author":"CJ Loland","year":"2012","unstructured":"Loland CJ et al (2012) R-modafinil (armodafinil): a unique dopamine uptake inhibitor and potential medication for psychostimulant abuse. Biol Psychiatry 72(5):405\u2013413","journal-title":"Biol Psychiatry"},{"issue":"4","key":"11_CR85","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1021\/acschemneuro.8b00340","volume":"10","author":"JD Keighron","year":"2019","unstructured":"Keighron JD et al (2019) Effects of (R)-modafinil and modafinil analogues on dopamine dynamics assessed by voltammetry and microdialysis in the mouse nucleus accumbens shell. ACS Chem Neurosci 10(4):2012\u20132021","journal-title":"ACS Chem Neurosci"},{"issue":"8","key":"11_CR86","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1038\/s41386-019-0366-z","volume":"44","author":"AH Newman","year":"2019","unstructured":"Newman AH et al (2019) Translating the atypical dopamine uptake inhibitor hypothesis toward therapeutics for treatment of psychostimulant use disorders. Neuropsychopharmacology 44(8):1435\u20131444","journal-title":"Neuropsychopharmacology"},{"issue":"23","key":"11_CR87","doi-asserted-by":"publisher","first-page":"10676","DOI":"10.1021\/acs.jmedchem.6b01373","volume":"59","author":"J Cao","year":"2016","unstructured":"Cao J et al (2016) Novel and high affinity 2-[(diphenylmethyl)sulfinyl]acetamide (Modafinil) analogues as atypical dopamine transporter inhibitors. J Med Chem 59(23):10676\u201310691","journal-title":"J Med Chem"},{"issue":"9","key":"11_CR88","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1038\/npp.2017.41","volume":"42","author":"HY Zhang","year":"2017","unstructured":"Zhang HY et al (2017) The novel modafinil analog, JJC8-016, as a potential cocaine abuse pharmacotherapeutic. Neuropsychopharmacology 42(9):1871\u20131883","journal-title":"Neuropsychopharmacology"},{"key":"11_CR89","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.neuropharm.2017.12.006","volume":"131","author":"BJ Tunstall","year":"2018","unstructured":"Tunstall BJ et al (2018) Atypical dopamine transporter inhibitors attenuate compulsive-like methamphetamine self-administration in rats. Neuropharmacology 131:96\u2013103","journal-title":"Neuropharmacology"},{"key":"11_CR90","doi-asserted-by":"publisher","first-page":"100033","DOI":"10.1124\/jpet.124.002356","volume":"392","author":"MI Allen","year":"2024","unstructured":"Allen MI et al (2024) Contrasting the reinforcing effects of the novel dopamine transport inhibitors JJC8-088 and JJC8-091 in monkeys: potential translation to medication assisted treatment. J Pharmacol Exp Ther 392:100033","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"11_CR91","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1124\/jpet.122.001363","volume":"384","author":"O Rahimi","year":"2023","unstructured":"Rahimi O et al (2023) The effects of the dopamine transporter ligands JJC8-088 and JJC8-091 on cocaine versus food choice in rhesus monkeys. J Pharmacol Exp Ther 384(3):372\u2013381","journal-title":"J Pharmacol Exp Ther"},{"key":"11_CR92","unstructured":"Business Wire (2024) Melior Discovery announces spinout of Melior Pharmaceuticals II, LLC. Available from: https:\/\/www.businesswire.com\/news\/home\/20160510005485\/en\/Melior-Discovery-Announces-Spinout-Melior-Pharmaceuticals-II"},{"issue":"1","key":"11_CR93","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/S0014-2999(97)01407-6","volume":"340","author":"RR Gainetdinov","year":"1997","unstructured":"Gainetdinov RR et al (1997) Effects of a psychostimulant drug sydnocarb on rat brain dopaminergic transmission in vivo. Eur J Pharmacol 340(1):53\u201358","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"11_CR94","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1124\/jpet.111.178947","volume":"337","author":"JA Gruner","year":"2011","unstructured":"Gruner JA et al (2011) Characterization of pharmacological and wake-promoting properties of the dopaminergic stimulant sydnocarb in rats. J Pharmacol Exp Ther 337(2):380\u2013390","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"11_CR95","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/biomedicines9060634","volume":"9","author":"S Aggarwal","year":"2021","unstructured":"Aggarwal S et al (2021) Functional characterization of the dopaminergic psychostimulant sydnocarb as an allosteric modulator of the human dopamine transporter. Biomedicines 9(6):634","journal-title":"Biomedicines"},{"key":"11_CR96","doi-asserted-by":"publisher","first-page":"2043","DOI":"10.1111\/jnc.16179","volume":"168","author":"CN Pedersen","year":"2024","unstructured":"Pedersen CN et al (2024) Cryo-EM structure of the dopamine transporter with a novel atypical non-competitive inhibitor bound to the orthosteric site. J Neurochem 168:2043","journal-title":"J Neurochem"},{"issue":"3","key":"11_CR97","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1124\/molpharm.121.000400","volume":"101","author":"O Refai","year":"2022","unstructured":"Refai O et al (2022) Allosteric modulator KM822 attenuates behavioral actions of amphetamine in Caenorhabditis elegans through interactions with the dopamine transporter DAT-1. Mol Pharmacol 101(3):123\u2013131","journal-title":"Mol Pharmacol"},{"issue":"6","key":"11_CR98","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1016\/j.pneurobio.2005.04.003","volume":"75","author":"D Sulzer","year":"2005","unstructured":"Sulzer D et al (2005) Mechanisms of neurotransmitter release by amphetamines: a review. Prog Neurobiol 75(6):406\u2013433","journal-title":"Prog Neurobiol"},{"issue":"8","key":"11_CR99","first-page":"CD007813","volume":"2018","author":"X Castells","year":"2018","unstructured":"Castells X, Blanco-Silvente L, Cunill R (2018) Amphetamines for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev 2018(8):CD007813","journal-title":"Cochrane Database Syst Rev"},{"issue":"3","key":"11_CR100","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1176\/appi.focus.130302","volume":"13","author":"B Namdari","year":"2015","unstructured":"Namdari B, Kollins SH (2015) Stimulants: abuse and performance enhancement (or lack thereof). Focus 13(3):283\u2013289","journal-title":"Focus"},{"issue":"suppl 1","key":"11_CR101","doi-asserted-by":"publisher","first-page":"i16","DOI":"10.1136\/bjsm.2006.027557","volume":"40","author":"L Avois","year":"2006","unstructured":"Avois L et al (2006) Central nervous system stimulants and sport practice. Br J Sports Med 40(suppl 1):i16\u2013i20","journal-title":"Br J Sports Med"},{"issue":"8","key":"11_CR102","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1001\/archpsyc.1976.01770080101010","volume":"33","author":"MW Fischman","year":"1976","unstructured":"Fischman MW et al (1976) Cardiovascular and subjective effects of intravenous cocaine administration in humans. Arch Gen Psychiatry 33(8):983\u2013989","journal-title":"Arch Gen Psychiatry"},{"issue":"3","key":"11_CR103","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1007\/BF00413242","volume":"5","author":"CL Scheckel","year":"1964","unstructured":"Scheckel CL, Boff E (1964) Behavioral effects of interacting imipramine and other drugs with d-amphetamine, cocaine, and tetrabenazine. Psychopharmacologia 5(3):198\u2013208","journal-title":"Psychopharmacologia"},{"issue":"3","key":"11_CR104","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/0091-3057(90)90296-T","volume":"35","author":"GR Wenger","year":"1990","unstructured":"Wenger GR, Wright DW (1990) Behavioral effects of cocaine and its interaction with d-amphetamine and morphine in rats. Pharmacol Biochem Behav 35(3):595\u2013600","journal-title":"Pharmacol Biochem Behav"},{"issue":"2","key":"11_CR105","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/j.psc.2013.02.005","volume":"36","author":"DEMD Rusyniak","year":"2013","unstructured":"Rusyniak DEMD (2013) Neurologic manifestations of chronic methamphetamine abuse. Psychiatr Clin N Am 36(2):261\u2013275","journal-title":"Psychiatr Clin N Am"},{"key":"11_CR106","doi-asserted-by":"publisher","first-page":"114391","DOI":"10.1016\/j.expneurol.2023.114391","volume":"364","author":"Y-P Fu","year":"2023","unstructured":"Fu Y-P, Wang Y (2023) Amphetamines abuse and depression: focus on TRPC channels. Exp Neurol 364:114391\u2013114391","journal-title":"Exp Neurol"},{"issue":"4","key":"11_CR107","doi-asserted-by":"publisher","first-page":"779","DOI":"10.12669\/pjms.40.4.8737","volume":"40","author":"SH Alamri","year":"2024","unstructured":"Alamri SH (2024) Young-onset dementia following chronic abuse of amphetamine-type stimulants. Pak J Med Sci 40(4):779\u2013781","journal-title":"Pak J Med Sci"},{"issue":"8","key":"11_CR108","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/acn3.51113","volume":"7","author":"NS Tzeng","year":"2020","unstructured":"Tzeng NS et al (2020) Association between amphetamine-related disorders and dementia-a nationwide cohort study in Taiwan. Ann Clin Transl Neurol 7(8):1284\u20131295","journal-title":"Ann Clin Transl Neurol"},{"key":"11_CR109","volume-title":"StatPearls","author":"JM Mullen","year":"2024","unstructured":"Mullen JM, Richards JR, Crawford AT (2024) Amphetamine-related psychiatric disorders. In: StatPearls. StatPearls Publishing, Treasure Island"},{"issue":"2","key":"11_CR110","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1111\/j.1527-3458.2004.tb00007.x","volume":"10","author":"RW Freudenmann","year":"2004","unstructured":"Freudenmann RW, Spitzer M (2004) The neuropsychopharmacology and toxicology of 3,4-methylenedioxy-N-ethyl-amphetamine (MDEA). CNS Drug Rev 10(2):89\u2013116","journal-title":"CNS Drug Rev"},{"issue":"2","key":"11_CR111","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0091-3057(99)00170-7","volume":"65","author":"M Barrionuevo","year":"2000","unstructured":"Barrionuevo M et al (2000) Serotonergic deficits and impaired passive-avoidance learning in rats by MDEA: a comparison with MDMA. Pharmacol Biochem Behav 65(2):233\u2013240","journal-title":"Pharmacol Biochem Behav"},{"key":"11_CR112","unstructured":"Methylphenidate Monograph for Professionals (2024) [cited 2024 Feb 14]. Available from: https:\/\/www.drugs.com\/monograph\/methylphenidate.html"},{"issue":"3","key":"11_CR113","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/j.bcp.2005.04.032","volume":"70","author":"DE Dar","year":"2005","unstructured":"Dar DE, Mayo C, Uhl GR (2005) The interaction of methylphenidate and benztropine with the dopamine transporter is different than other substrates and ligands. Biochem Pharmacol 70(3):461\u2013469","journal-title":"Biochem Pharmacol"},{"issue":"2","key":"11_CR114","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/S0014-2999(99)00274-5","volume":"373","author":"S Izenwasser","year":"1999","unstructured":"Izenwasser S et al (1999) Chronic methylphenidate alters locomotor activity and dopamine transporters differently from cocaine. Eur J Pharmacol 373(2):187\u2013193","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"11_CR115","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s00213-005-2221-7","volume":"181","author":"A Torres-Reveron","year":"2005","unstructured":"Torres-Reveron A, Dow-Edwards DL (2005) Repeated administration of methylphenidate in young, adolescent, and mature rats affects the response to cocaine later in adulthood. Psychopharmacologia 181(1):38\u201347","journal-title":"Psychopharmacologia"},{"issue":"1","key":"11_CR116","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.bbr.2012.01.008","volume":"229","author":"JK Argento","year":"2012","unstructured":"Argento JK, Arvanitogiannis A, Flores C (2012) Juvenile exposure to methylphenidate reduces cocaine reward and alters netrin-1 receptor expression in adulthood. Behav Brain Res 229(1):202\u2013207","journal-title":"Behav Brain Res"},{"issue":"1","key":"11_CR117","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.drugalcdep.2006.07.004","volume":"87","author":"FR Levin","year":"2007","unstructured":"Levin FR et al (2007) Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 87(1):20\u201329","journal-title":"Drug Alcohol Depend"},{"issue":"38","key":"11_CR118","doi-asserted-by":"publisher","first-page":"16667","DOI":"10.1073\/pnas.1011455107","volume":"107","author":"RZ Goldstein","year":"2010","unstructured":"Goldstein RZ et al (2010) Oral methylphenidate normalizes cingulate activity in cocaine addiction during a salient cognitive task. Proc Natl Acad Sci 107(38):16667\u201316672","journal-title":"Proc Natl Acad Sci"},{"issue":"5","key":"11_CR119","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0063023","volume":"8","author":"GJ Wang","year":"2013","unstructured":"Wang GJ et al (2013) Long-term stimulant treatment affects brain dopamine transporter level in patients with attention deficit hyperactive disorder. PLoS One 8(5):e63023","journal-title":"PLoS One"},{"key":"11_CR120","doi-asserted-by":"publisher","first-page":"1208120","DOI":"10.3389\/fpsyt.2023.1208120","volume":"14","author":"P van Ruitenbeek","year":"2023","unstructured":"van Ruitenbeek P et al (2023) Methylphenidate as a treatment option for substance use disorder: a transdiagnostic perspective. Front Psych 14:1208120","journal-title":"Front Psych"},{"issue":"4","key":"11_CR121","doi-asserted-by":"publisher","first-page":"451.e7","DOI":"10.1016\/j.genhosppsych.2012.05.010","volume":"35","author":"HMD Delavenne","year":"2013","unstructured":"Delavenne HMD et al (2013) Psychosis in a cocaine-dependent patient with ADHD during treatment with methylphenidate. Gen Hosp Psychiatry 35(4):451.e7\u2013451.e9","journal-title":"Gen Hosp Psychiatry"},{"key":"11_CR122","doi-asserted-by":"publisher","first-page":"61","DOI":"10.2147\/SAR.S50807","volume":"6","author":"KM D\u00fcrsteler","year":"2015","unstructured":"D\u00fcrsteler KM et al (2015) Clinical potential of methylphenidate in the treatment of cocaine addiction: a review of the current evidence. Subst Abus Rehabil 6:61\u201374","journal-title":"Subst Abus Rehabil"},{"key":"11_CR123","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/B978-0-12-374228-5.00019-6","volume-title":"Complementary and alternative therapies and the aging population","author":"EJ Richer","year":"2009","unstructured":"Richer EJ (2009) Chapter 19 \u2013 Ibogaine and the treatment of opiate addiction. In: Complementary and alternative therapies and the aging population. Elsevier Inc, pp 393\u2013401"},{"issue":"2","key":"11_CR124","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1556\/2054.01.2017.009","volume":"1","author":"AK Davis","year":"2017","unstructured":"Davis AK, Barsuglia JP, Windham-Herman AM, Lynch M, Polanco M (2017) Subjective effectiveness of ibogaine treatment for problematic opioid consumption: short- and long-term outcomes and current psychological functioning. J Psychedelic Stud 1(2):65\u201373","journal-title":"J Psychedelic Stud"},{"key":"11_CR125","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/bs.pbr.2018.08.005","volume":"242","author":"T Calvey","year":"2018","unstructured":"Calvey T (2018) Ibogaine as a treatment for substance misuse: potential benefits and practical dangers. Prog Brain Res 242:217\u2013257","journal-title":"Prog Brain Res"},{"key":"11_CR126","first-page":"39","volume-title":"The alkaloids: chemistry and biology","author":"SD Glick","year":"2001","unstructured":"Glick SD, Maisonneuve IM, Szumlinski KK (2001) Chapter 2 \u2013 Mechanisms of action of ibogaine: relevance to putative therapeutic effects and development of a safer iboga alkaloid congener. In: The alkaloids: chemistry and biology. Elsevier Science & Technology, pp 39\u201353"},{"issue":"1","key":"11_CR127","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/0014-2999(91)90634-3","volume":"199","author":"IM Maisonneuve","year":"1991","unstructured":"Maisonneuve IM, Keller RW, Glick SD (1991) Interactions between ibogaine, a potential anti-addictive agent, and morphine: an in vivo microdialysis study. Eur J Pharmacol 199(1):35\u201342","journal-title":"Eur J Pharmacol"},{"issue":"3","key":"11_CR128","doi-asserted-by":"publisher","first-page":"135a","DOI":"10.1016\/j.bpj.2010.12.943","volume":"100","author":"W Sandtner","year":"2011","unstructured":"Sandtner W et al (2011) Effects by ibogaine on the dopamine transporter. Biophys J 100(3):135a","journal-title":"Biophys J"},{"issue":"40","key":"11_CR129","doi-asserted-by":"publisher","first-page":"29441","DOI":"10.1074\/jbc.M704456200","volume":"282","author":"MT Jacobs","year":"2007","unstructured":"Jacobs MT et al (2007) Ibogaine, a noncompetitive inhibitor of serotonin transport, acts by stabilizing the cytoplasm-facing state of the transporter. J Biol Chem 282(40):29441\u201329447","journal-title":"J Biol Chem"},{"issue":"2","key":"11_CR130","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/0014-2999(92)90340-A","volume":"212","author":"IM Maisonneuve","year":"1992","unstructured":"Maisonneuve IM, Glick SD (1992) Interactions between ibogaine and cocaine in rats: in vivo microdialysis and motor behavior. Eur J Pharmacol 212(2):263\u2013266","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"11_CR131","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/j.1527-3458.1999.tb00084.x","volume":"5","author":"SD Glick","year":"1999","unstructured":"Glick SD et al (1999) (\u00b1)-18-Methoxycoronaridine: a novel iboga alkaloid congener having potential anti-addictive efficacy. CNS Drug Rev 5(1):27\u201342","journal-title":"CNS Drug Rev"},{"issue":"2","key":"11_CR132","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/S0006-8993(98)00527-7","volume":"800","author":"D Wei","year":"1998","unstructured":"Wei D et al (1998) Acute iboga alkaloid effects on extracellular serotonin (5-HT) levels in nucleus accumbens and striatum in rats. Brain Res 800(2):260\u2013268","journal-title":"Brain Res"},{"issue":"10","key":"11_CR133","doi-asserted-by":"publisher","first-page":"2160","DOI":"10.1016\/j.cell.2023.04.010","volume":"186","author":"I Singh","year":"2023","unstructured":"Singh I et al (2023) Structure-based discovery of conformationally selective inhibitors of the serotonin transporter. Cell 186(10):2160\u20132175.e17","journal-title":"Cell"},{"issue":"2","key":"11_CR134","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0014-2999(93)90212-Z","volume":"241","author":"SLT Cappendijk","year":"1993","unstructured":"Cappendijk SLT, Dzoljic MR (1993) Inhibitory effects of ibogaine on cocaine self-administration in rats. Eur J Pharmacol 241(2):261\u2013265","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"11_CR135","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/S0014-2999(00)00325-3","volume":"398","author":"KK Szumlinski","year":"2000","unstructured":"Szumlinski KK, Maisonneuve IM, Glick SD (2000) Differential effects of ibogaine on behavioural and dopamine sensitization to cocaine. Eur J Pharmacol 398(2):259\u2013262","journal-title":"Eur J Pharmacol"}],"container-title":["Advances in Neurobiology","Monoamine Transporters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-031-96364-3_11","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T19:04:04Z","timestamp":1776798244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/978-3-031-96364-3_11"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9783031963636","9783031963643"],"references-count":135,"URL":"https:\/\/doi.org\/10.1007\/978-3-031-96364-3_11","relation":{},"ISSN":["2190-5215","2190-5223"],"issn-type":[{"value":"2190-5215","type":"print"},{"value":"2190-5223","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]},"assertion":[{"value":"7 October 2025","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}